Prof. Rene Henricus Maria Verheijen

Professor and Head
UMC Utrecht, Netherlands

Highest Degree
Ph.D. in Gynaecological Oncology from Radboud University Nijmegen, Netherlands

My URL
https://livedna.org/31.32342

Share this Profile

Area of Interest:

Biomedical Sciences
Gynecology and Obstetrics
Oncology
Ovarian Cancer
Immunotherapy

Selected Publications

  1. Rusch, P., T. Ind, R. Kimmig, A. Maggioni and J. Ponce et al., 2019. Recommendations for a standardised educational program in robot assisted gynaecological surgery: Consensus from the Society of European Robotic Gynaecological Surgery (SERGS). Facts Views Vis. ObGyn, 11: 29-41.
    Direct Link  |  

  2. Arteaga De Castro, C.S., J.P. Hoogendam, I.M.L. Van Kalleveen, A.J.E. Raaijmakers and R.P. Zweemer et al., 2019. Proton MRS of cervical cancer at 7 T. NMR in Biomed., Vol. 32. 10.1002/nbm.4015.
    CrossRef  |  Direct Link  |  

  3. Verheijen, R.H.M., 2018. Training and Proctoring in Robotic Gynaecological Surgery. In: Textbook of Gynecologic Robotic Surgery, El-Gobashy, A., T. Ind, J. Persson and J.F. Magrina (Eds.)., Springer, Germany, ISBN: 978-3-319-63429-6, pp: 5-8.

  4. Rusch, P., R. Kimmig, F. Lecuru, J. Persson, J. Ponce, M. Degueldre and R. Verheijen, 2018. The society of european robotic gynaecological surgery (SERGS) pilot curriculum for robot assisted gynecological surgery. Arch. Gynecol. Obstetr., 297: 415-420.
    Direct Link  |  

  5. Garritsen, F.M., R.H. Verheijen, C.G. Gerestein, A.D. Van Zuilen and J.A. Oosterhaven et al., 2018. Is there an increased risk of cervical neoplasia in atopic dermatitis patients treated with oral immunosuppressive drugs?. J. Eur. Acad. Dermatol. Venereol., 32: 271-275.
    CrossRef  |  Direct Link  |  

  6. Van Kalleveen, I.M.L., J.P. Hoogendam, A.J.E. Raaijmakers, F. Visser and C.S. Arteaga De Castro et al., 2017. Boosting the SNR by adding a receive‐only endorectal monopole to an external antenna array for high‐resolution, T2‐weighted imaging of early‐stage cervical cancer with 7‐T MRI. NMR Biomed., Vol. 30. 10.1002/nbm.3750.
    CrossRef  |  Direct Link  |  

  7. Polman, N.J., M.H. Uijterwaal, B.I. Witte, J. Berkhof and F.J. Van Kemenade et al., 2017. Good performance of p16/ki‐67 dual‐stained cytology for surveillance of women treated for high‐grade CIN. Int. J. Cancer, 140: 423-430.
    CrossRef  |  Direct Link  |  

  8. Hoogendam, J.P., I.M. Kalleveen, C.S.A. De Castro, A.J. Raaijmakers and R.H. Verheijen et al., 2017. High-resolution T 2-weighted cervical cancer imaging: a feasibility study on ultra-high-field 7.0-T MRI with an endorectal monopole antenna. Eur. Radiol., 27: 938-945.
    Direct Link  |  

  9. Hoogendam, J.P., C.A. Vlek, P.O. Witteveen, R.H.M. Verheijen and R.P. Zweemer, 2017. Surgical lymph node assessment in mucinous ovarian carcinoma staging: A systematic review and meta‐analysis. BJOG Int. J. Obstetr. Gynaecol., 124: 370-378.
    CrossRef  |  Direct Link  |  

  10. Gan, C., M. Bossart, J. Piek, M. Halaska and D. Haidopoulos et al., 2017. Robotic and advanced laparoscopic surgical training in european gynecological oncology trainees. Int. J. Gynecol. Cancer, 27: 375-381.
    CrossRef  |  Direct Link  |  

  11. Becker, J.H. and R.H.M. Verheijen, 2017. Locally advanced cervix cancer: Staging by scan or by surgery?. BJOG: Int. J. Obstetr. Gynaecol., 124: 1096-1096.
    CrossRef  |  Direct Link  |  

  12. Zusterzeel, P.L., F.J. Pol, M. Van Ham, R.P. Zweemer, R.L. Bekkers, L.F. Massuger and R.H. Verheijen, 2016. Vaginal radical trachelectomy for early-stage cervical cancer: Increased recurrence risk for adenocarcinoma. Int. J. Gynecol. Cancer, 26: 1293-1299.
    CrossRef  |  Direct Link  |  

  13. Verheijen, R.H. and R.P. Zweemer, 2016. Screening to improve ovarian cancer prognosis?. Lancet, 387: 921-923.

  14. Soletormos, G., M.J. Duffy, S.O.A. Hassan, R.H. Verheijen and B. Tholander et al., 2016. Clinical use of cancer biomarkers in epithelial ovarian cancer: Updated guidelines from the European group on tumor markers. Int. J. Gynecol. Cancer, 26: 43-51.
    Direct Link  |  

  15. Rachel Skinner, S., C.M. Wheeler, B. Romanowski, X. Castellsague and E. Lazcano‐Ponce, 2016. Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. Int. J. Cancer, 138: 2428-2438.
    CrossRef  |  Direct Link  |  

  16. Luttmer, R., M.G. Dijkstra, P.J. Snijders, J. Berkhof and F.J. Van Kemenade et al., 2016. p16/Ki-67 dual-stained cytology for detecting cervical (pre) cancer in a HPV-positive gynecologic outpatient population. Modern Pathol., 29: 870-878.
    Direct Link  |  

  17. Luttmer, R., L.M. De Strooper, M.G. Dijkstra, J. Berkhof and P.J. Snijders et al., 2016. FAM19A4 methylation analysis in self-samples compared with cervical scrapes for detecting cervical (pre) cancer in HPV-positive women. Br. J. Cancer, 115: 579-587.
    Direct Link  |  

  18. Luttmer, R., L.M. De Strooper, J. Berkhof, P.J. Snijders, M.G. Dijkstra, M.H. Uijterwaal et al., 2016. Comparing the performance of FAM19A4 methylation analysis, cytology and HPV16/18 genotyping for the detection of cervical (pre) cancer in high‐risk HPV‐positive women of a gynecologic outpatient population (COMETH study). Int. J. Cancer, 138: 992-1002.
    CrossRef  |  Direct Link  |  

  19. Jauniaux, E. and R.H.M. Verheijen, 2016. Diagnosis and management of hydatidiform mole and its complications: 2000 years of a medical challenge. BJOG-An Int. J. Obstet. Gynaecol., Vol. 123. 10.1111/1471-0528.13940..
    CrossRef  |  Direct Link  |  

  20. Hoogendam, J.P., R.P. Zweemer, M.G. Hobbelink, M.A. Van Den Bosch, R.H. Verheijen and W.B. Veldhuis, 2016. 99mTc-nanocolloid SPECT/MRI fusion for the selective assessment of nonenlarged sentinel lymph nodes in patients with early-stage cervical cancer. J. Nucl. Med., 57: 551-556.
    Direct Link  |  

  21. Zaal, A., M.A. De Wilde, M.J. Duk, G.C. Graziosi and M. Van Haaften, 2015. The diagnostic process of cervical cancer; areas of good practice and windows of opportunity. Gynecol. Oncol., 138: 405-410.
    CrossRef  |  Direct Link  |  

  22. Veersema, S., H. Schreuder and R. Verheijen, 2015. Hysteroscopic resection of a placental site trophoblastic nodule with a hysteroscopic tissue removal system. J. Minim. Invas. Gynecol., Vol. 22. .
    Direct Link  |  

  23. Van Der Marel, J., A. Rodriguez, M. Del Pino, R. Van Baars and D. Jenkins et al., 2015. The value of endocervical curettage in addition to biopsies in women referred to colposcopy. J. Lower Gen. Tract Dis., 19: 282-287.
    CrossRef  |  Direct Link  |  

  24. Van Der Aa, J.E., J.P. Hoogendam, E.S. Butter, M.G. Ausems, R.H. Verheijen and R.P. Zweemer, 2015. The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy. Familial Cancer, 14: 539-544.
    Direct Link  |  

  25. Piek, J., M. Bossart, K. Boor, M. Halaska and D. Haidopoulos et al., 2015. The work place educational climate in gynecological oncology fellowships across Europe: The impact of accreditation. Int. J. Gynecol. Cancer, 25: 180-190.
    CrossRef  |  Direct Link  |  

  26. Louwers, J.A., A. Zaal, M. Kocken, J. Berkhof, E. Papagiannakis, P.J.F. Snijders and R.H. M. Verheijen, 2015. The performance of Dynamic Spectral Imaging colposcopy depends on indication for referrals. Gynecol. Oncol., 139: 452-457.
    CrossRef  |  Direct Link  |  

  27. Louwers, J.A., A. Zaal, M. Kocken, E. Papagiannakis, C.J.L.M. Meijer and R.H.M. Verheijen, 2015. Women's preferences of dynamic spectral imaging colposcopy. Gynecol. Obstetr. Investig., 79: 239-243.
    CrossRef  |  Direct Link  |  

  28. Hoogendam, J.P., W.B. Veldhuis, M.G. Hobbelink, R.H. Verheijen, M.A. Van Den Bosch and R.P. Zweemer, 2015. 99mTc SPECT/CT versus planar lymphoscintigraphy for preoperative sentinel lymph node detection in cervical cancer: A systematic review and metaanalysis. J. Nucl. Med., 56: 675-680.
    Direct Link  |  

  29. Hoogendam, J.P., R.P. Zweemer, H.M. Verkooijen, P.A. De Jong, M.A. Van Den Bosch, R. H. Verheijen and W.B. Veldhuis, 2015. No value for routine chest radiography in the work-up of early stage cervical cancer patients. PloS One, Vol. 10. 10.1371/journal.pone.0131899.
    CrossRef  |  Direct Link  |  

  30. Breijer, M.C., N. Van Hanegem, N.C.M. Visser, R.H.M. Verheijen and B.W.J. Mol et al., 2015. Does probability guided hysteroscopy reduce costs in women investigated for postmenopausal bleeding?. Sci. World J., 10.1155/2015/605312.
    CrossRef  |  Direct Link  |  

  31. Zaal, A., R.P. Zweemer, M. Zikan, L. Dusek and D. Querleu et al., 2014. Pelvic lymphadenectomy improves survival in patients with cervical cancer with low-volume disease in the sentinel node: A retrospective multicenter cohort study. Int. J. Gynecol. Cancer, 24: 303-311.
    CrossRef  |  Direct Link  |  

  32. Van Der Marel, J., R. Van Baars, W.G.V. Quint, J. Berkhof and M. Del Pino et al., 2014. The impact of human papillomavirus genotype on colposcopic appearance: A cross‐sectional analysis. BJOG Int. J. Obstetr. Gynaecol., 121: 1117-1126.
    CrossRef  |  Direct Link  |  

  33. Van Der Marel, J., R. Van Baars, A. Rodriguez, W.G.V. Quint and M.M. Van De Sandt et al., 2014. The increased detection of cervical intraepithelial neoplasia when using a second biopsy at colposcopy. Gynecol. Oncol., 135: 201-207.
    CrossRef  |  Direct Link  |  

  34. Uijterwaal, M.H., M. Kocken, J. Berkhof, R.L. Bekkers and R.H. Verheijen et al., 2014. Posttreatment assessment of women at risk of developing high-grade cervical disease: proposal for new guidelines based on data from the Netherlands. J. Lower Gen. Tract Dis., 18: 338-343.
    CrossRef  |  Direct Link  |  

  35. Skinner, S.R., A. Szarewski, B. Romanowski, S.M. Garland and E. Lazcano-Ponce et al., 2014. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet, 384: 2213-2227.
    CrossRef  |  Direct Link  |  

  36. Schreuder, H.W., J.E. Persson, R.G. Wolswijk, I. Ihse, M.P. Schijven and R.H. Verheijen, 2014. Validation of a novel virtual reality simulator for robotic surgery. Sci. World J., 30: 1-11.

  37. Hoogendam, J.P., R.H.M. Verheijen, I. Wegner and R.P. Zweemer, 2014. Oncological outcome and long‐term complications in robot‐assisted radical surgery for early stage cervical cancer: An observational cohort study. BJOG Int. J. Obstet. Gynaecol., 121: 1538-1545.
    CrossRef  |  Direct Link  |  

  38. Despierre, E., B.T. Yesilyurt, S. Lambrechts, N. Johnson and R. Verheijen et al., 2014. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment. Int. J. Gynecol. Cancer, 24: 468-477.
    CrossRef  |  Direct Link  |  

  39. Manchanda, R., M. Godfrey, L.A. Wong-Taylor, M.J. Halaska and M. Burnell et al., 2013. The need for accredited training in gynaecological oncology: A report from the European network of young gynaecological oncologists (ENYGO). Ann. Oncol., 24: 944-952.
    Direct Link  |  

  40. Lybol, C., C.M.G. Thomas, E.A. Blanken, F.C.G.J. Sweep and R.H. Verheijen et al., 2013. Comparing cisplatin-based combination chemotherapy with EMA/CO chemotherapy for the treatment of high risk gestational trophoblastic neoplasia. Eur. J. Cancer, 49: 860-867.
    CrossRef  |  Direct Link  |  

  41. Hoogendam, J.P., M.G. Hobbelink, W.B. Veldhuis, R.H. Verheijen, P.J. Van Diest and R.P. Zweemer, 2013. Preoperative sentinel node mapping with 99mTc-nanocolloid SPECT–CT significantly reduces the intraoperative sentinel node retrieval time in robot assisted laparoscopic cervical cancer surgery. Gynecol. Oncol., 129: 389-394.
    CrossRef  |  Direct Link  |  

  42. Hoogendam, J.P., A. Zaal, E.G. Rutten, C.J. Heijnen and G.G. Kenter et al., 2013. Detection of cervical cancer recurrence during follow-up: a multivariable comparison of 9 frequently investigated serum biomarkers. Gynecol. Oncol., 131: 655-660.
    CrossRef  |  Direct Link  |  

  43. De Fouw, M., S. Meijer, R.H.M. Verheijen and Q.C. Van Rossum-Schornagel, 2013. Tweelingzwangerschap met complete mola hydatidosa: diagnostische valkuil bij bloedverlies in het eerste trimester. Case report Complete Mola. Ned Tijdschr Verloskunde Gynaecol., 126: 218-224.
    Direct Link  |  

  44. Bijron, J.G., C.A. Seldenrijk, R.P. Zweemer, J.G. Lange, R.H. Verheijen and P.J. Van Diest, 2013. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: A novel metastatic route in early pelvic carcinogenesis. Am. J. Surg. Pathol., 37: 1123-1130.
    CrossRef  |  Direct Link  |  

  45. Zaal, A., W.J. Peyrot, P.M.J.J. Berns, M.E. Van Der Burg and J.H. Veerbeek et al., 2012. Genomic aberrations relate early and advanced stage ovarian cancer. Cell. Oncol., 35: 181-188.
    Direct Link  |  

  46. Zaal, A., J.A. Louwers, J. Berkhof, M. Kocken and W.A.T. Harmsel et al., 2012. Agreement between colposcopic impression and histological diagnosis among human papillomavirus type 16‐positive women: A clinical trial using dynamic spectral imaging colposcopy. BJOG Int. J. Obstetr. Gynaecol., 119: 537-544.
    CrossRef  |  Direct Link  |  

  47. Verheijen, R.H., D. Cibula, P. Zola and N. Reed, 2012. On behalf of council of the european society of gynaecologic oncology. cancer antigen 125: Lost to follow-up? A European society of gynaecological oncology consensus statement. Int. J. Gynecol. Cancer, 22: 170-174.

  48. Verheijen, R.H., D. Cibula, P. Zola and N. Reed, 2012. Cancer antigen 125: Lost to follow-up?. Int. J. Gynecol. Cancer, 22: 170-174.
    CrossRef  |  Direct Link  |  

  49. Verheijen, R. and R. Zweemer, 2012. Robotic surgery for gynaecologic cancer: An overview. Curr. Oncol. Rep., 14: 544-549.
    Direct Link  |  

  50. Van Der Marel, J., W. Quint, F. Smedts, D. Jenkins, R. Verheijen and T. Helmerhorst, 2012. Changing human papillomavirus genotype attribution in squamous preneoplastic lesions studied by laser capture microscopy–polymerase chain reaction in a diethylstilbestrol‐exposed woman during 8 years of follow‐up. Histopathology, 61: 987-989.
    CrossRef  |  Direct Link  |  

  51. Van De Lande, J., S.V. Mensdorff-Pouilly, R.G. Lettinga, J.M. Piek and R.H. Verheijen, 2012. Open versus laparoscopic pelvic lymph node dissection in early stage cervical cancer: No difference in surgical or disease outcome. Int. J. Gynecol. Cancer, 22: 107-114.
    CrossRef  |  Direct Link  |  

  52. Schuurman, T.N., A. Stiekema, J.H. Van Leeuwen Schagen and R.H. Verheijen, 2012. Systematic lymphadenectomy in patients with clinical stage II endometrial carcinoma: a case report and review of the literature. Eur. J. Gynaecol. Oncol., 33: 530-533.
    Direct Link  |  

  53. Schreuder, H.W., T.O. Pattij, R.P. Zweemer, M.W. Van Baal and R.H. Verheijen, 2012. Increasing experience in laparoscopic staging of early ovarian cancer. Gynecol. Surgery, 9: 89-96.

  54. Schreuder, H.W., R. Wolswijk, R.P. Zweemer, M.P. Schijven and R.H. Verheijen, 2012. Training and learning robotic surgery, time for a more structured approach: A systematic review. BJOG: Int. J. Obstetr. Gynaecol., 119: 137-149.
    CrossRef  |  Direct Link  |  

  55. Rijkaart, D.C., J. Berkhof, F.J.V. Kemenade, V.M. Coupe and A.T. Hesselink et al., 2012. Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screening. Int. J. Cancer, 130: 602-610.
    CrossRef  |  Direct Link  |  

  56. Rijkaart, D.C., J. Berkhof, F.J. Van Kemenade, V.M.H. Coupe and L. Rozendaal et al., 2012. HPV DNA testing in population-based cervical screening (VUSA-Screen study): Results and implications. Br. J. Cancer, 106: 975-981.
    Direct Link  |  

  57. Rijkaart, D.C., D.A.M. Heideman, V.M.H. Coupe, A.A.T.P. Brink and R.H.M. Verheijen et al., 2012. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J. Clin. Microbiol., 50: 2390-2396.
    CrossRef  |  Direct Link  |  

  58. Lybol, C., D.W. Centen, C.M.G. Thomas, M.J. Ten Kate‐Booij and R.H.M. Verheijen et al., 2012. Fatal cases of gestational trophoblastic neoplasia over four decades in the Netherlands: A retrospective cohort study. BJOG Int. J. Obstetr. Gynaecol., 119: 1465-1472.
    CrossRef  |  Direct Link  |  

  59. Louwers, J.A., J. Berkhof, A. Zaal, M. Kocken and L. Rozendaal et al., 2012. HrHPV-testing in a university hospital gynecology outpatient clinic: Recommendations for clinical practice. Gynecol. Oncol., 124: 518-524.
    CrossRef  |  Direct Link  |  

  60. Colombo, N., G. Gitsch, N. Reed, F. Amant and D. Cibula et al., 2012. ESGO statement on the role of CA‐125 measurement in follow-up of epithelial ovarian cancer. Int. J. Gynecol. Cancer, 22: 175-175.
    Direct Link  |  

  61. Cibula, D., N.R. Abu-Rustum, L. Dusek, M. Zikan and A. Zaal et al., 2012. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol. Oncol., 124: 496-501.
    CrossRef  |  Direct Link  |  

  62. Cibula, D., N.R. Abu-Rustum, L. Dusek, J. Slama and M. Zikan et al., 2012. Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis. Gynecologic Oncol., 127: 462-466.
    CrossRef  |  

  63. Breijer, M., J.A.H. Peeters, B.C. Opmeer, T.J. Clark and R.H.M. Verheijen et al., 2012. Capacity of endometrial thickness measurement to diagnose endometrial carcinoma in asymptomatic postmenopausal women: a systematic review and meta‐analysis. Ultrasound Obstetr. Gynecol., 40: 621-629.
    CrossRef  |  Direct Link  |  

  64. Bijron, J.G., P. Van Der Groep, E.B. Van Dorst, L.M. Seeber, D.M. Sie-Go, R.H. Verheijen and P.J. Van Diest, 2012. Promoter hypermethylation patterns in fallopian tube epithelium of BRCA1 and BRCA2 germ line mutation carriers. Endocrine Related Cancer, 19: 69-81.

  65. Bijron, J.G., G.M. Bol, R.H. Verheijen and P.J. Van Diest, 2012. Epigenetic biomarkers in the diagnosis of ovarian cancer. Exp. Opin. Med. Diagnost., 6: 421-438.
    CrossRef  |  Direct Link  |  

  66. Verleye, L., P.B. Ottevanger, G.B. Kristensen, T. Ehlen and N. Johnson et al., 2011. Quality of pathology reports for advanced ovarian cancer: Are we missing essential information?: An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur. J. Cancer, 47: 57-64.
    CrossRef  |  Direct Link  |  

  67. Verheijen, R.H., 2011. Comparing bivalent and quadrivalent HPV vaccines. Br. Med. J., Vol. 343. 10.1136/bmj.d5720.
    CrossRef  |  Direct Link  |  

  68. Seeber, L.M., N. Horrée, M.A. Vooijs, A.P.M. Heintz, E. van der Wall, R.H. Verheijen and P.J. Van Diest, 2011. The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit. Rev. Oncol./Hematol., 78: 173-184.
    CrossRef  |  Direct Link  |  

  69. Schreuder, H.W.R., C.B.V.D. Berg, E.J. Hazebroek, R.H.M. Verheijen and M.P. Schijven, 2011. Laparoscopic skills training using inexpensive box trainers: Which exercises to choose when constructing a validated training course. BJOG: Int. J. Obstet. Gynaecol., 118: 1576-1584.
    CrossRef  |  Direct Link  |  

  70. Schreuder, H.W., P.D.V. Hove, J.A. Janse, R.R. Verheijen, L.P. Stassen and J. Dankelman, 2011. An “intermediate curriculum” for advanced laparoscopic skills training with virtual reality simulation. J. Minim. Invas. Gynecol., 18: 597-606.
    CrossRef  |  Direct Link  |  

  71. Mensdorff-Pouilly, V., M. Moreno and R.H. Verheijen, 2011. Natural and induced humoral responses to MUC1. Cancers, 3: 3073-3103.
    CrossRef  |  Direct Link  |  

  72. Louwers, J.A., A. Zaal, M. Kocken, W.A.T. Harmsel and G.C.M. Graziosi et al., 2011. Dynamic spectral imaging colposcopy: Higher sensitivity for detection of premalignant cervical lesions. BJOG: Int. J. Obstetr. Gynaecol., 118: 309-318.
    CrossRef  |  Direct Link  |  

  73. Kocken, M., T.J. Helmerhorst, J. Berkhof, J.A. Louwers and M.A. Nobbenhuis et al., 2011. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: A long-term multi-cohort study. Lancet Oncol., 12: 441-450.
    CrossRef  |  Direct Link  |  

  74. Cibula, D., R. Verheijen, A. Lopes, F. Amant and U. Beller et al., 2011. Training in bowel and upper abdominal surgery in gynaecological oncology: European society of gynecological oncology (ESGO) statement. Int. J. Gynecol. Cancer, 21: 1264-1265.
    CrossRef  |  Direct Link  |  

  75. Cibula, D., R. Verheijen, A. Lopes and L. Dusek, 2011. Current clinical practice in cytoreductive surgery for advanced ovarian cancer: A European survey. Int. J. Gynecol. Cancer, 21: 1219-1224.
    CrossRef  |  Direct Link  |  

  76. Vergote, I., C.G. Tropé, F. Amant, G.B. Kristensen and T. Ehlen et al., 2010. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New Engl. J. Med., 363: 943-953.
    CrossRef  |  Direct Link  |  

  77. Seeber, L.M., R.P. Zweemer, L. Marchionni, L.F. Massuger and V.T. Smit et al., 2010. Methylation profiles of endometrioid and serous endometrial cancers. Endocrine-Related Cancer, 17: 663-673.
    CrossRef  |  Direct Link  |  

  78. Seeber, L.M., N. Horrée, P. van der Groep, E. van der Wall, R.H. Verheijen and P.J. van Diest, 2010. Necrosis related HIF-1α expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC Cancer, Vol. 10. 10.1186/1471-2407-10-307.
    CrossRef  |  Direct Link  |  

  79. Seeber, L., R.P. Zweemer, R.H. Verheijen and P.J. van Diest, 2010. Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstetr. Gynecol. Int., Vol. 2010. 10.1155/2010/580971.
    CrossRef  |  Direct Link  |  

  80. Schreuder, H.W.R., R.P. Zweemer, W.M. Van Baal, J. Van De Lande, J.C. Dijkstra and R.H.M. Verheijen, 2010. From open radical hysterectomy to robot-assisted laparoscopic radical hysterectomy for early stage cervical cancer: aspects of a single institution learning curve. Gynecol. Surg., 7: 253-258.
    CrossRef  |  Direct Link  |  

  81. Rijkaart, D.C., V.M.H. Coupe, F.J. Van Kemenade, D.A.M. Heideman and A.T. Hesselink et al., 2010. Comparison of hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test. Br. J. Cancer, 103: 939-946.
    CrossRef  |  Direct Link  |  

  82. Rijkaart, D.C., J. Berkhof, F.J. van Kemenade, L. Rozendaal and R.H. Verheijen et al., 2010. Comparison of HPV and cytology triage algorithms for women with borderline or mild dyskaryosis in population‐based cervical screening (VUSA‐screen study). Int. J. Cancer, 126: 2175-2181.
    CrossRef  |  Direct Link  |  

  83. Reed, N., D. Milan, R. Verheijen and M. Castiglione, 2010. Non epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annal Oncol., 21: 31-36.

  84. Oonk, M.H., B.M. van Hemel, H. Hollema, J.A. de Hullu and A.C. Ansink et al., 2010. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: Results from GROINSS-V, a multicentre observational study. Lancet Oncol., 11: 646-652.
    CrossRef  |  Direct Link  |  

  85. Nowee, M.E., L.M. Seeber, N. Horrée, A.M. Snijders, P.J. Van Diest, R.H. Verheijen and J.C. Dorsman, 2010. Array comparative genomic hybridization analysis indicates that serous carcinomas of the ovary, fallopian tube and endometrium are distinct entities. Histopathology, 57: 634-637.
    CrossRef  |  Direct Link  |  

  86. Louwers, J.A., M. Kocken, J.C. van der Bijl, J. Berkhof, P.J. Snijders, C.J. Meijer and R.H. Verheijen, 2010. Colposcopic characteristics of high-risk human papillomavirus-related cervical lesions. J. Lower Genital Tract Dis., 14: 49-55.
    CrossRef  |  Direct Link  |  

  87. Hoogendam, J.P., W.M. Klerkx, G.A. de Kort, S. Bipat and R.P. Zweemer et al., 2010. The influence of the b‐value combination on apparent diffusion coefficient based differentiation between malignant and benign tissue in cervical cancer. J. Magnet. Resonance Imaging, 32: 376-382.
    CrossRef  |  Direct Link  |  

  88. Verhoeven, M.O., M.J. van der Mooren, T. Teerlink, R.H. Verheijen, P.G. Scheffer and P. Kenemans, 2009. The influence of physiological and surgical menopause on coronary heart disease risk markers. Menopause, 16: 37-49.
    CrossRef  |  Direct Link  |  

  89. Verbruggen, M.B., P.J. Van Diest, J.P. Baak, M.A. Broeckaert, P. Kenemans and R.H. Verheijen, 2009. The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: A prospective study. Int. J. Gynecol. Pathol., 28: 35-40.
    CrossRef  |  Direct Link  |  

  90. Verbruggen, M.B., N.L. Sieben, G.M. Roemen, D.A. Rockx, P.J. van Diest, R.H. Verheijen and J.C. Dorsman, 2009. v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior. Int. J. Gynecol. Cancer, Vol. 19. 10.1111/IGC.0b013e3181a83119.
    CrossRef  |  Direct Link  |  

  91. Van de Lande, J., E.M. Davelaar, S. von Mensdorff-Pouilly, T.J. Water and J. Berkhof et al., 2009. SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer. Gynecol. Oncol., 112: 119-125.
    CrossRef  |  Direct Link  |  

  92. Schreuder, H.W.R., E. van Santbrink and R.H.M. Verheijen, 2009. Laparoscopy curriculum for residents on the Netherlands. J. Min. Inv. Gynecol., 16: s57-s58.

  93. Schreuder, H.W.R. and R.H.M. Verheijen, 2009. Robotic surgery. BJOG., 116: 198-213.

  94. Louwers, J.A., M. Kocken, W.A. Ter Harmsel and R.H.M. Verheijen, 2009. Digital colposcopy: Ready for use? An overview of literature. BJOG: Int. J. Obstet. Gynaecol., 116: 220-229.
    CrossRef  |  Direct Link  |  

  95. Korse, C.M., J.M. Bonfrer, M. Van Beurden, R.H. Verheijen and M.A. Rookus, 2009. Estradiol and testosterone levels are lower after oophorectomy than after natural menopause. Tumor Biol., 30: 37-42.
    CrossRef  |  Direct Link  |  

  96. Bais, A.G., M.J.C. Eijkemans, M. Rebolj, P.J.F. Snijders and R.H.M. Verheijen et al., 2009. Post‐treatment CIN: Randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease. Int. J. Cancer, 124: 889-895.
    CrossRef  |  Direct Link  |  

  97. Bais, A.G., M.J. Eijkemans, M. Rebolj, P.J. Snijders and R.H. Verheijen et al., 2009. Post‐treatment CIN: Randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease. Int. J. Cancer, 124: 889-895.
    CrossRef  |  Direct Link  |  

  98. Verbruggen, M.B., R.H.M. Verheijen, F.R.W.V.D. Goot, M.V. Beurden and J.C. Dorsman, 2008. Sereuze borderline-ovariumtumor in supradiafragmatische lymfklieren. Ned Tijdschr Oncol., 5: 27-32.

  99. Van der Zee, A.G., M.H. Oonk, J.A. De Hullu, A.C. Ansink and I. Vergote et al., 2008. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J. Clin. Oncol., 26: 884-889.
    Direct Link  |  

  100. Piek, J.M.J., R.H. Verheijen and P.J. Diest, 2008. Genese van het sereuze ovariumcarcinoom, een paradigmashift?. Ned. Tijdschr. voor Oncologie, 5: 304-309.

  101. Oei, A.L.M., M. Moreno, R.H.M. Verheijen, F.C.G.J. Sweep and C.M.G. Thomas et al., 2008. Induction of igg antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int. J. Cancer., 123: 1848-1853.
    CrossRef  |  Direct Link  |  

  102. Mota, F., I. Vergote, J.B. Trimbos, F. Amant and N. Siddiqui et al., 2008. Classification of radical hysterectomy adopted by the Gynecological Cancer group of the European organization for research and treatment of cancer. Int. J. Gynecol. Cancer, 26: 884-889.
    CrossRef  |  Direct Link  |  

  103. Moreno, M., J.W. Molling, S.V. Mensdorff-Pouilly, R.H. Verheijen and E. Hooijberg ., 2008. IFN-γ-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. J. Immunol., 181: 2446-2454.
    CrossRef  |  Direct Link  |  

  104. Heideman, D.A.M., P.J.F. Snijders, J. Berkhof, R.H.M. Verheijen, T.J.M. Helmerhorst and C.J.L.M. Meijer, 2008. Vaccination against HPV: Indications for women and the impact on the cervical screening programme. BJOG: Int. J. Obstetr. Gynaecol., 115: 938-946.
    CrossRef  |  Direct Link  |  

  105. Davelaar, E.M., J.V.D. Lande, S.V. Mensdorff-Pouilly, M.A. Blankenstein, R.H. Verheijen and P. Kenemans, 2008. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. Tumor Biol., 29: 9-17.
    CrossRef  |  Direct Link  |  

  106. Verbruggen, M.B., R.P. Zweemer, J.M.J. Piek, G.A.V. Unnik and P.J.V. Diest et al., 2007. A case of loss of heterozygosity in the BRCA2 gene of a borderline ovarian tumor: Case report and review of literatur. Int. J. Gynecol. Cancer, 17: 1143-1147.
    CrossRef  |  Direct Link  |  

  107. Seters, V.M., F.J.T. Kate, M.V. Beurden, R.H. Verheijen, C.J. Meijer, M.P. Burger and T.J. Helmerhorst, 2007. In the absence of (early) invasive carcinoma, vulvar intraepithelial neoplasia associated with lichen sclerosus is mainly of undifferentiated type: New insights in histology and aetiology. J. Clin. Pathol., 60: 504-508.

  108. Oei, A.L., R.H. Verheijen, M.V. Seiden, B.B. Benigno and A. Lopes et al., 2007. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium‐90‐labeled murine HMFG1 without improvement in overall survival. Int. J. Cancer, 120: 2710-2714.
    CrossRef  |  Direct Link  |  

  109. Nowee, M.E., J.C. Dorsman, J.M.J. Piek, V.M. Kosma, K. Hämäläinen, R.H.M. Verheijen and P.J.V. Diest, 2007. HER‐2/neu and p27Kip1 in progression of Fallopian tube carcinoma: An immunohistochemical and array comparative genomic hybridization study. Histopathology, 51: 666-673.
    CrossRef  |  Direct Link  |  

  110. Nowee, M.E., A.M. Snijders, D.A.P. Rockx, R.M.D. Wit, V.M. Kosma, K. Hämäläinen and J.C. Dorsman, 2007. DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation‐dependent probe amplification. J. Pathol., 213: 46-55.
    CrossRef  |  Direct Link  |  

  111. Moreno, M., H.J. Bontkes, R.J. Scheper, P. Kenemans, R.H. Verheijen and V.S. Mensdorff-Pouilly, 2007. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett., 257: 47-55.

  112. Lande, J.V.D., B. Torrenga, P.G. Raijmakers, O.S. Hoekstra, M.W.V. Baal, Brölmann, H.A. and R.H. Verheijen, 2007. Sentinel lymph node detection in early stage uterine cervix carcinoma: A systematic review. Gynecol. Oncol., 106: 604-613.
    CrossRef  |  Direct Link  |  

  113. Hermsen, B.B.J., R.I. Olivier, R.H.M. Verheijen, M.V. Beurden and J.D. Hullu et al., 2007. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; An observational follow-up study. Br. J. Cancer, 96: 1335-1342.
    CrossRef  |  Direct Link  |  

  114. Hermsen, B.B.J., R.H.M. Verheijen, F.H. Menko, J.J.P. Gille and K.V. Uffelen et al., 2007. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. Europ. J. Cancer, 43: 1556-1563.
    CrossRef  |  Direct Link  |  

  115. Hermsen, B.B., S.V. Mensdorff-Pouilly, J. Berkhof, P.J.V. Diest and J.J. Gille et al., 2007. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer. J. Clin. Oncol., 25: 1383-1389.
    Direct Link  |  

  116. Gok, M., V.M. Coupe, J. Berkhof, R.H. Verheijen and T.J. Helmerhorst et al., 2007. HPV16 and increased risk of recurrence after treatment for CIN. Gynecologic Oncol., 104: 273-275.

  117. Coupe, V.M.H., J. Berkhof, R.H.M. Verheijen and C.J.L.M. Meijer, 2007. Cost‐effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG Int. J. Obstetr. Gynaecol., 114: 416-424.
    CrossRef  |  Direct Link  |  

  118. Bulkmans, N.W.J., J. Berkhof, L. Rozendaal, F.J.V. Kemenade and A.J.P. Boeke et al. 2007. High-risk human papillomavirus testing detects clinically relevant high-grade cervical intraepithelial neoplasia earlier than cytology in cervical screening permitting extension of the screening interval: Five-year follow-up results of the randomised controlled POBASCAM trial. Lancet, 370: 1764-1772.

  119. Bulk, S., N.W. Bulkmans, J. Berkhof, L. Rozendaal and P. Boeke et al., 2007. Risk of high‐grade cervical intra‐epithelial neoplasia based on cytology and high‐risk HPV testing at baseline and at 6‐months. Int. J. Cancer, 121: 361-367.
    CrossRef  |  Direct Link  |  

  120. Bais, A.G., F. J.V. Kemenade, J. Berkhof, R.H. Verheijen and P.J. Snijders et al., 2007. Human papillomavirus testing on self‐sampled cervicovaginal brushes: An effective alternative to protect nonresponders in cervical screening programs. Int. J. Cancer, 120: 1505-1510.

  121. Verheijen, R.H., L.F. Massuger, B.B. Benigno, A.A. Epenetos and A. Lopes et al., 2006. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. J. Clin. Oncol., 24: 571-578.
    CrossRef  |  Direct Link  |  

  122. Verbruggen, M.B., R.H. Verheijen, F.R.V. De Goot, V.M. Beurden, J.C. Dorsman and P.J. V. Diest, 2006. Serous borderline tumor of the ovary presenting with cervical lymph node involvement: A report of 3 cases. Am. J. Surg. Pathol., 30: 739-743.
    Direct Link  |  

  123. Van Der Groep, P., A. Bouter, R. Van Der Zanden, I. Siccama and F.H. Menko et al., 2006. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J. Clin. Pathol., 59: 611-617.
    CrossRef  |  Direct Link  |  

  124. Piek, J.M., J.C. Dorsman, L.F. Massuger, A.C. Ansink and J. Weegenaar, 2006. BRCA1 and p53 protein expression in cultured ovarian surface epithelial cells derived from women with and without a BRCA1 germline mutation. Arch. Gynecol. Obstetr., 274: 327-331.
    Direct Link  |  

  125. Madalinska, J.B., M.V. Beurden, E.M. Bleiker, H.B. Valdimarsdottir, J. Hollenstein et al., 2006. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J. Clin. Oncol., 24: 3576-3582.
    CrossRef  |  Direct Link  |  

  126. Kocken, M., J.A. Louwers, J.M. Helmerhorst, C.J.L.M. Meijer and W.G.F. Quint et al., 2006. Vaccinatie ter preventie van cervixcarcinoom. Ned Tijdschr Med. Microbiol., 14: 22-26.

  127. Hermsen, B.B., P.J.V. Diest, J. Berkhof, F.H. Menko and J.J. Gille et al., 2006. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int. J. Cancer, 119: 1412-1418.
    CrossRef  |  Direct Link  |  

  128. Green, J.A., E.M.J.J. Berns, C. Coens, I.V. Luijk and J. Thompson-Hehir et al., 2006. Alterations in the p53 pathway and prognosis in advanced ovarian cancer: A multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). Eur. J. Cancer, 42: 2539-2548.
    CrossRef  |  Direct Link  |  

  129. Craanen, M.E., B.V. Triest, R.H.M. Verheijen and C.J.J. Mulder, 2006. Thalidomide in refractory haemorrhagic radiation induced proctitis. Gut., 55: 1371-1372.
    CrossRef  |  Direct Link  |  

  130. Brink, A.T.P., P.J.F. Snijders, C.J.L.M. Meijer, J. Berkhof and R.H.M. Verheijen, 2006. HPV testing in cervical screening. Best Pract Res. Clin. Obst. Gynaecol., 20: 253-266.

  131. Berkhof, J., M.C. De Bruijne, G.D. Zielinski, N.W. Bulkmans and L. Rozendaal et al., 2006. Evaluation of cervical screening strategies with adjunct high‐risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int. J. Cancer, 118: 1759-1768.
    CrossRef  |  Direct Link  |  

  132. Berkhof, J., F.J.V. Kemenade, P.J. Snijders, R.H. Verheijen and C.J. Meijer, 2006. When to test women for human papillomavirus: Testing is possible without increasing colposcopy referral rate. BMJ, Vol. 332. 10.1136/bmj.332.7535.237 .
    CrossRef  |  Direct Link  |  

  133. Vermorken, J.B., M.K.B. Parmar, M.F. Brady, E.A. Eisenhauer and T. Hogberg et al., 2005. Clinical trials in ovarian carcinoma: Study methodology. Ann. Oncol., 16: viii20-viii29.
    CrossRef  |  Direct Link  |  

  134. Vasen, H.F.A., E. Tesfay, H. Boonstra, M.J.E. Mourits and E. Rutgers et al., 2005. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur. J. Cancer, 41: 549-554.
    CrossRef  |  Direct Link  |  

  135. Van Trommel, N.E., L.F. Massuger, R.H. Verheijen, F.C. Sweep and C.M. Thomas, 2005. The curative effect of a second curettage in persistent trophoblastic disease: A retrospective cohort survey. Gynecol. Oncol., 99: 6-13.
    CrossRef  |  Direct Link  |  

  136. Mensdorff-Pouilly, V.S., L. Kinarsky, K. Engelmann, S.E. Baldus, P. Maurer, 2005. B lymphocyte responses to variant and non-variant repeat clusters of human tumor mucin MUC1 are controlled by peptide conformation and O-glycosylation. Glycobiology, 15: 735-746.

  137. Madalinska, J.B., J. Hollenstein, E.M.A. Bleiker, M.V. Beurden, H.B. Valdimarsdottir et al., 2005. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J. Clin. Oncol., 23: 6890-6898.
    Direct Link  |  

  138. Hermsen, B.B., S. von Mensdorff-Pouilly, H.F. Fabry, H.A. Winters, P. Kenemans, R.H. Verheijen and P.J. van Diest, 2005. Lobulitis is a frequent finding in prophylactically removed breast tissue from women at hereditary high risk of breast cancer. J. Pathol., 206: 220-223.
    PubMed  |  

  139. Bulk, S., O. Visser, L. Rozendaal, R.H. Verheijen and C.J. Meijer, 2005. Cervical cancer in the Netherlands 1989–1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int. J. Cancer, 113: 1005-1009.
    CrossRef  |  Direct Link  |  

  140. Bais, A.G., M. Rebolj, P.J. Snijders, F.A. De Schipper and D.A.V. Der Meulen et al., 2005. Triage using HPV‐testing in persistent borderline and mildly dyskaryotic smears: Proposal for new guidelines. Int. J. Cancer, 116: 122-129.
    CrossRef  |  Direct Link  |  

  141. Baak, J.P.A., G.L. Mutter, A. Steinbakk, L. Taddele and B.V. Diermen et al., 2005. Objective Biomarkers in Endometrioid-Type Endometrial Carcinogenesis. In: Cancer Chemoprevention, Kellof, G.J., E.T. Hawk and C.C. Sigman (Eds.)., Humana Press Inc., Totowa, pp: 463-470.

  142. Baak, J.P., G.L. Mutter, S. Robboy, P.J.V. Diest and A.M. Uyterlinde, 2005. The molecular genetics and morphometry‐based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer. Int. J. Am. Cancer Society, 103: 2304-2312.
    CrossRef  |  Direct Link  |  

  143. Zielinski, G.D., A.G. Bais, T.J. Helmerhorst, R.H. Verheijen and F.A. De Schipper et al., 2004. HPV testing and monitoring of women after treatment of CIN 3: Review of the literature and meta-analysis. Obstetr. Gynecol. Survey, 59: 543-553.
    Direct Link  |  

  144. Steenbergen, R.D., D. Kramer, B.J. Braakhuis, P.L. Stern, R.H. Verheijen, C.J. Meijer and P.J. Snijders, 2004. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J. Natl. Cancer Inst., 96: 294-305.
    Direct Link  |  

  145. Pijpers, R., M.R. Buist, A.V. Lingen, J. Dijkstra and P.J.V. Diest et al., 2004. The sentinel node in cervical cancer: Scintigraphy and laparoscopic gamma probe-guided biopsy. Eur. J. Nucl. Med. Mol. Imag., 31: 1479-1486.
    Direct Link  |  

  146. Piek, J.M., P. Kenemans and R.H. Verheijen, 2004. Intraperitoneal serous adenocarcinoma: A critical appraisal of three hypotheses on its cause. Am. J. Obstetr. Gynecol., 191: 718-732.
    CrossRef  |  Direct Link  |  

  147. Piek, J.M., J.C. Dorsman, A. Shvarts, A.C. Ansink and L.F. Massuger, 2004. Cultures of ovarian surface epithelium from women with and without a hereditary predisposition to develop female adnexal carcinoma. Gynecol. Oncol., 92: 819-826.
    CrossRef  |  Direct Link  |  

  148. Kenemans, P., R.A. Verstraeten and R.H.M. Verheijen, 2004. Oncogenic pathways in hereditary and sporadic breast cancer. Maturitas, 49: 34-43.

  149. Hesselink, A.T., A.J.V. Den Brule, A.A. Brink, J. Berkhof, F.J.V. Kemenade, R.H. Verheijen and P.J. Snijders, 2004. Comparison of hybrid capture 2 with in situ hybridization for the detection of high‐risk human papillomavirus in liquid‐based cervical samples. Cancer Cytopathol. Interdiscip. Int. J. Am. Cancer Society, 102: 11-18.
    CrossRef  |  Direct Link  |  

  150. Bulkmans, N.W., L. Rozendaal, P.J. Snijders, F.J. Voorhorst and A.J.P. Boeke et al., 2004. POBASCAM, a population‐based randomized controlled trial for implementation of high‐risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 women. Int. J. Cancer, 110: 94-101.
    CrossRef  |  Direct Link  |  

  151. Zweemer, R.P., J.M.J. Piek, R.H.M. Verheijen, P.J.V. Diest, J.J.P. Gille, F.H. Menko and P. Kenemans, 2003. BRCA1-gerelateerd tubacarcinoom en consequenties voor preventie. Ned Tijdschr Obstet Gynaecol, 116: 85-87.

  152. Van Duin, M., R.D. Steenbergen, J. De Wilde, T.J. Helmerhorst and R.H. Verheijen et al., 2003. Telomerase activity in high‐grade cervical lesions is associated with allelic imbalance at 6Q14–22. Int. J. Cancer, 105: 577-582.
    CrossRef  |  Direct Link  |  

  153. Snijders, A.M., M.E. Nowee, J. Fridlyand, J.M. Pieka and J.C. Dorsman et al., 2003. Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in fallopian tube carcinoma. Oncogene, 22: 4281-4286.
    Direct Link  |  

  154. Pijpers, R., M.R. Buist, A.V. Lingen, J. Dijkstra, G.G.J. Teule, P. Kenemans, N.M. Bruin and R.H.M. Verheijen, 2003. De schildwachtklierbiopsie bij het cervixcarcinoom. Tijdschr Nucl Geneesk, 25: 24-27.

  155. Piek, J.M., R.H. Verheijen, P. Kenemans, L.F. Massuger, H. Bulten and V.P.J. Diest, 2003. BRCA1/2-related ovarian cancers are of tubal origin: A hypothesis. Gynecol. Oncol., Vol. 90. 10.1016/S0090-8258(03)00365-2.
    CrossRef  |  Direct Link  |  

  156. Piek, J.M., R.H. Verheijen, F.H. Menko, A.P. Jongsma and J. Weegenaar et al., 2003. Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition. Histopathology, 43: 26-32.
    CrossRef  |  Direct Link  |  

  157. Piek, J.M., J.C. Dorsman, R.P. Zweemer, R.H. Verheijen and P.J.V. Diest, 2003. Women harboring BRCA1/2 germline mutations are at risk for breast and female adnexal carcinoma. Int. J. Gynecol. Pathol., 22: 315-316.
    CrossRef  |  Direct Link  |  

  158. Piek, J.M., B. Torrenga, B. Hermsen, R.H. Verheijen and R.P. Zweemer, 2003. Histopathological characteristics of BRCA1-and BRCA2-associated intraperitoneal cancer: A clinic-based study. Familial Cancer, 2: 73-78.
    Direct Link  |  

  159. Monteiro, A.N., P. Devilee, S. Narod, E.H. Meijers-Heijboer, 2003. BRCA1 Syndrome. In: Pathology and Genetics Tumours of the Breast and Female Genital Organs, Tavassoli, F.A. and P. Devilee (Eds.)., IARC Press, Lyon, ISBN: 13-9789283224129, pp: 338-345..

  160. Foulkes, W.D., I.M. Stefansson, P.O. Chappuis, L.R. Begin and J.R. Goffin et al., 2003. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. JNCI J. Nat. Cancer Inst., 95: 1482-1485.
    CrossRef  |  Direct Link  |  

  161. Dols, A., S.L. Meijer, H.M. Hu, V. Goodell and M.L. Disis et al., 2003. Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J. Immunother., 26: 163-170.
    Direct Link  |  

  162. Bulk, S., O. Visser, L. Rozendaal, R.H.M. Verheijen and C.J.L.M. Meijer, 2003. Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br. J. Cancer, 89: 834-839.
    Direct Link  |  

  163. Buist, M.R., R.J. Pijpers, A. van Lingen, P.J. van Diest, J. Dijkstra, P. Kenemans and R.H.M. Verheijen, 2003. Laparoscopic detection of sentinel lymph nodes followed by lymph node dissection in patients with early stage cervical cancer. Gynecol. Oncol., 90: 290-296.
    CrossRef  |  

  164. Bouwmeester, F.W., A.R. Jonkhoff, R.H. Verheijen and H.P.V. Geijn, 2003. Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII. Obstetr. Gynecol., 101: 1174-1176.
    CrossRef  |  Direct Link  |  

  165. Adema, A.D., J. Cloos, R.H.M. Verheijen, B.J.M. Braakhuis and P.E. Bryant, 2003. Comparison of bleomycin and radiation in the G2 assay of chromatid breaks. Int. J. Radiat. Biol., 79: 655-661.
    CrossRef  |  Direct Link  |  

  166. Verheijen, R.H.M., H. Boonstra, F.H. Menko, J. De Graaff, H.F.A. Vasen and G.G. Kenter, 2002. Aanbevelingen voor het beleid bij vrouwen met een erfelijk bepaalde hoge kans op gynaecologische kanker. Nederlands Tijdschrift Voor Geneeskunde, 146: 2414-2418.

  167. Van Duin, M., P.J. Snijders, H.F. Schrijnemakers, F.J. Voorhorst, L. Rozendaal, M.A. Nobbenhuis and C.J. Meijer, 2002. Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance. Int. J. Cancer, 98: 590-595.
    CrossRef  |  Direct Link  |  

  168. Steenbergen, R.D., V.E.O. Engberink, D. Kramer, H.F. Schrijnemakers, R.H. Verheijen, C.J. Meijer and P.J. Snijders, 2002. Down-regulation of GATA-3 expression during human papillomavirus-mediated immortalization and cervical carcinogenesis. Am. J. Pathol., 160: 1945-1951.
    CrossRef  |  Direct Link  |  

  169. Shaw, P.A., J.R. McLaughlin, R.P. Zweemer, S.A. Narod and H. Risch et al., 2002. Histopathologic features of genetically determined ovarian cancer. Int. J. Gynecol. Pathol., 21: 407-411.
    Direct Link  |  

  170. Schutter, E.M., E.M. Davelaar, G.J. Van Kamp, R.A. Verstraeten, P. Kenemans and R.H. Verheijen, 2002. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am. J. Obstet. Gynecol., 187: 385-392.
    CrossRef  |  Direct Link  |  

  171. Nobbenhuis, M.A., T.J. Helmerhorst, A.J. van den Brule, L. Rozendaal and L.H. Jaspars et al., 2002. Primary screening for high risk HPV by home obtained cervicovaginal lavage is an alternative screening tool for unscreened women. J. Clin. Pathol., 55: 435-439.
    PubMed  |  

  172. Jongsma, A.P.M., J.M.J. Piek, R.P. Zweemer, R.H.M. Verheijen and J.K. Gebbinck et al., 2002. Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. Mol. Pathol., 55: 305-309.
    CrossRef  |  Direct Link  |  

  173. Zweemer, R.P., R.H. Verheijen, J.W.W. Coebergh, I.J. Jacobs and P.J. Van Diest et al., 2001. Survival analysis in familial ovarian cancer, a case control study. Eur. J. Obstetr. Gynecol. Reproduct. Biol., 98: 219-223.
    CrossRef  |  Direct Link  |  

  174. Zweemer, R.P., A. Ryan, A.M. Snijders, M.A. Hermsen and G.A. Meijer et al., 2001. Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab. Investigat., 81: 1363-1370.
    Direct Link  |  

  175. Van Zanten‐Przybysz, I., C.F. Molthoff, J.C. Roos, R.H. Verheijen and A. van Hof et al., 2001. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: iv vs. ip. Int. J. Cancer, 92: 106-114.
    CrossRef  |  Direct Link  |  

  176. Piek, J.M.J., P.J. van Diest, R.H.M. Verheijen and P. Kenemans, 2001. Cell cycle‐related proteins p21 and bcl‐2: Markers of differentiation in the human Fallopian tube. Histopathology, 38: 481-482.
    CrossRef  |  Direct Link  |  

  177. Piek, J.M., P.J. van Diest, R.P. Zweemer, P. Kenemans and R.H. Verheijen, 2001. Tubal ligation and risk of ovarian cancer. Lancet, 358: 844-844.
    Direct Link  |  

  178. Piek, J.M., P.J. van Diest, R.P. Zweemer, J.W. Jansen and R.J. Poort‐Keesom et al., 2001. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol., 195: 451-456.
    CrossRef  |  Direct Link  |  

  179. Nobbenhuis, M.A.E., C.J.L.M. Meijer, A.J.C. Van Den Brule, L. Rozendaal and F.J. Voorhorst et al., 2001. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br. J. Cancer, 84: 796-801.
    Direct Link  |  

  180. Nobbenhuis, M.A., T.J. Helmerhorst, A.J. van den Brule, L. Rozendaal and F.J. Voorhorst et al., 2001. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet, 358: 1782-1783.
    CrossRef  |  Direct Link  |  

  181. Baak, J.P., A. Ørbo, P.J. Van Diest, M. Jiwa and P. De Bruin et al., 2001. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am. J. Surg. Pathol., 25: 930-935.
    Direct Link  |  

  182. Zweemer, R.P., P.J. Van Diest, R.H. Verheijen, A. Ryan and J.J. Gille et al., 2000. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol. Oncol., 76: 45-50.
    CrossRef  |  Direct Link  |  

  183. Verheijen, R.H., R. Pijpers, P.J. van Diest, C.W. Burger, M.R. Buist and P. Kenemans, 2000. Sentinel node detection in cervical cancer. Obstet. Gynecol., 96: 135-138.
    CrossRef  |  PubMed  |  

  184. Van Zanten-Przybysz, I., C.F. Molthoff, J.C. Roos, M.A. Plaizier and G.W. Visser et al, 2000. Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J. Nucl. Med., 41: 1168-1176.
    PubMed  |  Direct Link  |  

  185. Van Duin, M., P.J. Snijders, M.T. Vossen, E. Klaassen and F. Voorhorst et al., 2000. Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. J. General Virol., 81: 317-325.
    Direct Link  |  

  186. Hage, J.J., J.J.M.L. Dekker, R.B. Karim, R.H.M. Verheijen and E. Bloemena, 2000. Ovarian cancer in female-to-male transsexuals: Report of two cases. Gynecol. Oncol., 76: 413-415.
    CrossRef  |  Direct Link  |  

  187. De Hullu, J.A., H. Hollema, D.A. Piers, R.H.M. Verheijen and P.J. Van Diest et al., 2000. Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J. Clin. Oncol., 18: 2811-2816.
    Direct Link  |  

  188. Zweemer, R.P., R.H.M. Verheijen, F.H. Menko, J.J.P. Gille and P.J. Van Diest et al., 1999. Differences between hereditary and sporadic ovarian cancer. Eur. J. Obstetr. Gynecol. Reprod. Biol., 82: 151-153.
    Direct Link  |  

  189. Zweemer, R.P., P.A. Shaw, R.M. Verheijen, A. Ryan and A. Berchuck et al., 1999. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J. Clin. Pathol., Vol. 52. 10.1136/jcp.52.5.372.
    CrossRef  |  Direct Link  |  

  190. Verheijen, R.H.M., S. von Mensdorff-Pouilly, G.J. van Kamp and P. Kenemans, 1999. CA125: Fundamental and clinical aspects. Sem. Cancer Biol., 9: 117-124.
    Direct Link  |  

  191. Van Zanten-Przybysz, I., C.F.M. Molthoff, G.W.M. Visser, R.M.H. Verheijen and M.A.B.D. Plaizier et al., 1999. I-131-labelled chimeric monoclonal antibody MOv18 in ovarian cancer patients: A pilot study. Tumor Target., 4: 179-188.

  192. Schutter, E.M., V. Mijatovic, A. Kok, G.K. Van, R. Verstraeten and R.H. Verheijen, 1999. Urinary Gonadotropin Peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study. Anticancer Res., 19: 5551-5557.
    Direct Link  |  

  193. Nijman, H.W., P. Kenemans, R.J. Poort-Keesom, R.A. Verstraeten and S. Mensdorff-Pouilly et al., 1999. Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer. Eur. J. Obstetr. Gynecol. Reprod. Biol., 83: 201-206.
    CrossRef  |  Direct Link  |  

  194. De Gruijl, T.D., H.J. Bontkes, J.M.W alboomers, P. Coursaget and M.J. Stukart et al., 1999. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J. General Virol., 80: 399-408.
    Direct Link  |  

  195. De Gruijl, T.D., H.J. Bontkes, F. Peccatori, M.P.W. Gallee and T.J. Helmerhorst et al., 1999. Expression of CD3-ζ on T-cells in primary cervical carcinoma and in metastasis-positive and-negative pelvic lymph nodes. Br. J. Cancer, 79: 1127-1132.
    Direct Link  |  

  196. Davies, Q., A.C. Perkins, J.C. Roos, C.F.M. Molthoff and R.H.M. Verheijen et al., 1999. An immunoscintigraphic evaluation of the engineered human monoclonal antibody (hCTMO1) for use in the treatment of ovarian carcinoma. BJOG: Int. J. Obstetr. Gynaecol., 106: 31-37.
    Direct Link  |  

  197. Bontkes, H.J., T.D. De Gruijl, J.M. Walboomers, J.T. Schiller and J. Dillner et al., 1999. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J. General Virol., 80: 409-417.
    Direct Link  |  

  198. Zweemer, R.P., R.H. Verheijen, J.J. Gille, P.J. van Dies, G. Pals and F.H. Menko, 1998. Clinical and genetic evaluation of thirty ovarian cancer families. Am. J. Obstetr. Gynecol., 178: 85-90.
    Direct Link  |  

  199. Snijders, P.J., M. van Duin, J.M. Walboomers, R.D. Steenbergen and E.K. Risse et al., 1998. Telomerase activity exclusively in cervical carcinomas and a subset of cervical intraepithelial neoplasia grade III lesions: Strong association with elevated messenger RNA levels of its catalytic subunit and high-risk human papillomavirus DNA. Cancer Res., 58: 3812-3818.
    Direct Link  |  

  200. Hopman, E.H., L. Rozendaal, R.H. Verheijen, P. Kenemans and T.J. Helmerhorst, 1998. Digital color imaging colposcopy: A matter of choice. Eur. J. Obstetr. Gynecol. Reproduct. Biol., 77: 229-234.
    CrossRef  |  

  201. De Gruijl, T.D., H.J. Bontkes, J.M. Walboomers, M.J. Stukart and F.S. Doekhie et al., 1998. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: A longitudinal study. Cancer Res., 586: 1700-1706.
    Direct Link  |  

  202. Broadhead, T.J., Q. Davies, A.C. van Hof, C.F.M. Molthoff and A.C. Perkins et al., 1998. Clinical study to investigate the potential of an engineered human monoclonal antibody, hCTM01, for targeted chemotherapy of ovarian cancer. Tumor Target, 3: 55-57.

  203. Bontkes, H.J., M. van Duin, T.D. de Gruijl, M.F. Duggan‐Keen and J.M. Walboomers et al., 1998. HPV 16 infection and progression of cervical intra‐epithelial neoplasia: Analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int. J. Cancer, 78: 166-171.
    Direct Link  |  

  204. Verheijen, R.H.M., 1997. Vroeg stadium cervixcarcinoom met lymfkliermetastasen: Rechtsomkeer of volle kracht vooruit? Ned. Tijdschr. Obstet. Gynaecol., 110: 33-34.

  205. Vennegoor, C.J., H.W. Nijman, J.W. Drijfhout, L. Vernie and R.A. Verstraeten et al., 1997. Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett., 116: 93-101.
    CrossRef  |  Direct Link  |  

  206. Van Rijswijk, R.E.N., K. Hoekman, C.W. Burger, R.H.M. Verheijen and J.B. Vermorken, 1997. Experience with intraperitoneal cisplatin and etoposide and iv sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease. Ann. Oncol., 8: 1235-1241.
    CrossRef  |  Direct Link  |  

  207. Molthoff, C.F.M., H.M. Prinssen, P. Kenemans, A.C. van Hoff, W. den Hollander and R.H.M. Verheijen, 1997. Escalating protein doses of chimeric monoclonal antibody Mov18 immunoglobulin G in ovarian carcinoma patients: A phase I study. Cancer, 80: 2712-2720.

  208. Gruijl, T.D.D., H.J. Bontkes, J.M. Walboomers, J.T. Schiller and M.J. Stukart et al., 1997. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J. Nat. Cancer Inst., 89: 630-638.
    Direct Link  |  

  209. Zweemer, R.P., F. Scheele, R.H. Verheijen, P. Hummel and R. Schats, 1996. Ovarian abscess during pregnancy mimicking a leiomyoma of the uterus: A complication of transvaginal ultrasound-guided oocyte aspiration. J. Assisted Reprod. Genet., 13: 81-85.
    CrossRef  |  Direct Link  |  

  210. Verheijen, R.H.M., 1996. Monoclonal antibody treatment: Which way to go? Tumor Target., 2: 195-196.

  211. Van Hof, A.C., C.F. Molthoff, Q. Davies, A.C. Perkins and R.H. Verheijen et al., 1996. Biodistribution of 111indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: Influence of protein dose. Cancer Res., 56: 5179-5185.
    Direct Link  |  

  212. De Gruijl, T.D., H.J. Bontkes, M.J. Stukart, J.M. Walboomers and A.J. Remmink et al., 1996. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection. J. General Virol., 77: 2183-2191.
    Direct Link  |  

  213. De Gruijl, T.D., H.J. Bontkes, J.M. Walboomers, M.J. Stukart and A.A. Robbesom et al., 1996. Analysis of IgG reactivity against human papillomavirus type‐16 E7 in patients with cervical intraepithelial neoplasm indicates an association with clearance of viral infection: Results of a prospective study. Int. J. Cancer, 686: 731-738.
    Direct Link  |  

  214. Bon, G.G., R.H.M. Verheijen, J.M. Zuetenhorst, G.J. van Kamp, A.A. Verstraeten and P. Kenemans, 1996. Mucin-like carcinoma-associated antigen (MCA) serum levels in patients with adenocarcinomas originating from ovary, breast and colon. Gynecol. Obstet. Invest., 42: 58-62.

  215. Verheijen, R.H.M., 1995. Familiair mammacarcinoom. Tijdschr voor Climacterium Postmenopauze, 9: 21-26.

  216. Kenemans, P., R.H.M. Verheijen and C.A. Yedema, 1995. Trofoblast tumoren-state of the art. Ned. Tijdschr. Obstet. Gynaecol., 104: 12-14.

  217. Hoek, A., F.J. Broekmans, R.H.M. Verheijen and R. Schats, 1995. Succesful treatment of an advanced interstitial pregnancy by sequential systemic and local administration of methotrexate. Hum. Reprod., 10: 1864-1865.

  218. Verheijen, R.H.M., F.H. Menko and P. Kenemans, 1994. Familiair ovarium carcinoom. Ned Tijdschr Geneesk, 138: 63-66.

  219. Menko, F.H., R.H. Verheijen, E. Everhardt, L.A. Louwé and J.T. Wijnen et al., 1994. Endometrial cancer in four sisters: Report of a kindred with presumed cancer family syndrome. Gynecol. Oncol., 54: 171-174.
    CrossRef  |  

  220. Yedema, K.A., R.H. Verheijen, P. Kenemans, C.P. Schijf, G.F. Borm, M.F. Segers and C.M. Thomas, 1993. Identification of patients with persistent trophoblastic disease by means of a normal human chorionic gonadotropin regression curve. Am. J. Obstetr. Gynecol., 168: 787-792.
    CrossRef  |  Direct Link  |  

  221. Yedema, C., S. von Mensdorff-Pouilly, P. Kenemans, R. Verheijen, G. Bon and J. Hilgers, 1993. Update on the Serum Tumour Marker CA 125. In: The Management of Adnexal Cysts, Bruhat (Ed.)., Blackwell, Oxford, pp: 75-98.

  222. Verheijen, R.H.M., 1993. Minimal invasive surgery: Endoscopy back in gynaecologic oncology. ECC Newsletter, 2: 8-9.

  223. Massuger, L.F.A.G., C.M.G. Thomas, M.F.G. Segers, F.H.M. Corstens, R.H.M. Verheijen, P. Kenemans and L.G. Poels, 1992. Detection of anti-idiotypic and anti-isotypic immunoresponses after immunoscintigraphy of ovarian cancer with Indium-111 labeled OV-TL 3 F(ab')2 monoclonal antibody. J. Nucl. Med., 33: 1958-1963.

  224. Verheijen, R.H.M., E.H.M. Bakker, C.P.T. Schijf, P.H.T. van der Zanden and P.W.J. van Dongen, 1991. Gynaecologische en obstetrische consequenties van blootstelling aan diëthylstilbestrol (DES) in utero herbelicht. Ned. Tijdschr Geneesk, 135: 89-93.

  225. Poeschmann, R.P., R.H. Verheijen and P.W. van Dongen, 1991. Differential diagnosis and causes of nonimmunological hydrops fetalis: A review. Obstetr. Gynecol. Survey, 46: 223-231.
    CrossRef  |  Direct Link  |  

  226. Massuger, L.F.A.G., R.A.M.J. Claessens, P. Kenemans, R.H.M. Verheijen and O.C. Boerman et al., 1991. Kinetics and biodistribution in relation to tumor detection with indium-111-labeled OV-TL 3 F(ab')2 in patients with ovarian cancer. Nucl. Med. Commun., 12: 593-609.

  227. Massuger, L.F.A.G., P. Kenemans, R.H.M. Verheijen, R.A.M.J. Claessens and F.H.M. Corstens, 1991. Detection and localization of ovarian cancer with radiolabeled monoclonal antibodies. Eur. J. Obstet. Gynecol. Repr. Biol., 37: 47-69.

  228. Verheijen, R.H.M., L.F.A.G. Massuger and P. Kenemans, 1990. Gerichte cytotoxische therapie met behulp van monoclonale antilichamen. Tijdschrift Kanker, 14: 240-242.

  229. Massuger, L.F., P. Kenemans, R.A. Claessens, R.H. Verheijen and C.P. Schijf et al., 1990. Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F (ab') 2 monoclonal antibody. J. Nucl. Med., 31: 1802-1810.
    Direct Link  |  

  230. Verheijen, R.H.M., L.F.A.G. Massuger, J. Schalken and P. Kenemans, 1989. Potential Clinical Applications of Oncogenes in Gynecologic Oncology. In: The Proc. of the XIIth World Congress of Gynecology and Obstetrics, Gynecologic Cancer, Belfort, P., J.A. Pinotti and T.K.A.B. Eskes (Eds.)., Vol. 3, The Parthenon Publishing Group, Carnforth/New Jersey, pp: 3-8.

  231. Verheijen, R.H.M., H.J.M. Van Rijen-De Rooij, A.A.J. Van Zundert and P.A. De Jong, 1989. Pregnancy in a patient with the Klippel-Trenaunay-Weber syndrome: A case report. Eur. J. Obstetr. Gynecol. Reproduct. Biol., 33: 89-94.
    CrossRef  |  Direct Link  |  

  232. Kenemans, P., L.F.A.G. Massuger, R.H.M. Verheijen, R.A.M.J. Claessens and F.H.M. Corstens, 1989. Tumor Imaging in Ovarian Cancer. In: The Proc. of The XIIth World Congress of Gynecology and Obstetrics, Gynecologic Cancer, Belfort, P., A. Pinotti and T.K.A.B. Eskes (Eds.)., Vol. 3, The Parthenon Publishing Group, Carnforth/New Jersey, pp: 49-55.

  233. Verheijen, R.H.M., L.F.A.G. Massuger, P. Kenemans, H.J. Haisma and A.A. Epenetos, 1988. Polymorphic epithelial mucin and CA125-bearing glycoprotein as targets for imaging and therapy with monoclonal antibodies. Cancer Rev., 11-12: 145-172.

  234. Kenemans, P., C.A. Yedema, J.H.M. Hilgers, L.F.A.G. Massuger, R.H.M. Verheijen, C.M.G. Thomas and L.G. Poels, 1988. Clinical applications of monoclonal antibodies against ovarian cancer-associated antigens. Eur. J. Obstetr. Gynecol. Reproduct. Biol., 29: 207-218.
    CrossRef  |  Direct Link  |  

  235. Kenemans, P., C.A. Yedema, T. Wobbes, E. Op't Rood, R. Verheijen, L. Poels and C. Thomas, 1987. Assay of SCC Antigen in Patients with Breast Cancer and other Adenocarcinomas. In: SCC in the Management of Squamous-Cell Carcinoma, Kato, H., H.W.A. De Bruyn, W. Elbert, R.B. Herberman and J.T. Johnson (Eds.)., Excerpta Medica, Lawerenceville, New York, pp: 86-95.

  236. Poels, L.G., D. Peters, Y. Van Megen, G.P. Vooijs and R.N.M. Verheyen et al., 1986. Monoclonal antibody against human ovarian tumor-associated antigens. J. Nat. Cancer Inst., 76: 781-791.
    Direct Link  |  

  237. Oud, P.S., D.J. Haag, D.J. Zahniser, F.C. Ramaekers and A.C. Huysmans et al., 1986. Cytopress: Automated slide preparation of cytologic material from suspension. Cytometry: J. Int. Soc. Anal. Cytol., 7: 8-17.
    CrossRef  |  Direct Link  |  

  238. Feitz, W.F.J., R.H.M. Verheyen, W.J. Kirkels, G.P. Vooys, F.M.J. Debruyne and C.J. Herman, 1986. Dynamics of human renal tumor colony growth in vitro. Urol. Res., 14: 109-112.
    CrossRef  |  Direct Link  |  

  239. Verheuen, R.H.M., W.F.J. Feitz, J.L.M. Beck, F.M.J. Debruyne, G.P. Vooys, P. Kenemans and C.J. Herman, 1985. Cell DNA content-correlation with clonogenicity in the Human Tumour Cloning System (HTCS). Int. J. Cancer, 35: 653-657.
    CrossRef  |  Direct Link  |  

  240. Verheijen, R.H.M., R.D.H. Whelan, W.F.J. Feitz, P. Kenemans, G.P. Vooys, C.J. Herman and B.T. Hill, 1985. Automated colony counting in Courtenay-Mills tumour cell cultures. Cell. Biol. Int. Rep., 9: 893-899.

  241. Verheijen, R.H.M., P. Oud, C. Verrijp, W. Feitz, P. Kenemans, P. Vooys and C. Herman, 1985. Colony isolation from soft agar cultures. J. Microsc, 137: RP1-RP2.

  242. Verheijen, R.H.M., L. Beex, D.J.T. Wagener and P. Kenemans, 1985. Cis-platinum in combination with low-dose adriamycin and cyclo¬phosphamide in advanced ovarian carcinoma. Eur. J. Gynecol. Oncol., 6: 116-120.

  243. Verheijen, R.H., W.F. Feitz, P. Kenemans, G.P. Vooys and C.J. Herman, 1985. Time course of ovarian tumour growth in soft agar culture. Br. J. Cancer, 52: 707-712.
    Direct Link  |  

  244. Kenemans, P., R.H.M. Verheijen, A.M. Leloux and L.G. Poels, 1985. Prospects and applications of monoclonal antibodies in gynecological oncology. Eur. J. Obstetr. Gynecol., 19: 340-346.
    CrossRef  |  Direct Link  |  

  245. Verheijen, R.H.M., C.J. Herman and P. Kenemans, 1984. Applications of a human tumour clonogenic cell culture system in gynaecological oncology: Review and personal experience. Eur. J. Obstetr. Gynecol. Reprod. Biol., 17: 43-51.
    CrossRef  |  Direct Link  |  

  246. Ramaekers, F.C., R.H. Verheijen, O. Moesker, A. Kant, G.P. Vooijs and C.J. Herman, 1983. Mesodermal mixed tumor. Diagnosis by analysis of intermediate filament proteins. Am. J. Surg. Pathol., 7: 381-385.
    Direct Link  |  

  247. Herman, C.J., O.E. Pelgrim, W.J. Kirkels, R. Verheijen, F.M. Debruyne, P. Kenemans and G.P. Vooijs, 1983. In‐use evaluation of the omnicon automated tumor colony counter. Cytometry: J. Intern. Soc. Anal. Cytol., 3: 439-442.
    CrossRef  |  
Member since February, 2020